Should I Buy AVR? AVR 2026 Analysis

Should You Buy Anteris Technologies Global Corp (AVR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

5.490

1 Day change

5.17%

52 Week Range

8.790

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: there is no Intellectia buy signal today, and near-term pattern probabilities lean slightly negative (next day/week/month).
Trend structure is generally bullish (SMA_5 > SMA_20 > SMA_200), but price is below the pivot (6.244) in pre-market (6.06), implying the stock is currently trading in a weaker zone.
Best near-term setup improves if AVR reclaims 6.244 (pivot) and holds above it; otherwise downside risk toward 5.86/5.63 support remains more likely than a fast upside breakout.

Technical Analysis

Price/levels: Pre-market 6.06 is below Pivot 6.244; nearby supports S1 5.862 and S2 5.626; resistances R1 6.626 and R2 6.862.
Trend: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating the broader trend is up.
Momentum: MACD histogram is positive (0.0163) but contracting, suggesting bullish momentum is fading.
RSI: RSI_6 at 47.44 is neutral; no strong overbought/oversold edge.
Pattern-based forward bias: ~50% odds of -1.14% next day, -1.52% next week, -2.08% next month (slight bearish drift).

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Medtronic strategic investment noted by the covering analyst is viewed as product validation and increases strategic/long-term optionality.
- Capital overhang reportedly relieved following the gross financing cited by the analyst.
- Earnings catalyst upcoming: 2026-02-18 (After Hours).

Neutral/Negative Catalysts

- Price is currently below a key pivot (6.244), which can cap near-term upside unless reclaimed.
- No recent news momentum in the last week.
- Short-horizon statistical pattern points to mild downside drift over the next day/week/month.
- Dilution impact from financing was explicitly cited as the reason for the price target cut.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 429,000, down -44.21% YoY (weak top-line trend).
Net income: -22.244M, improved 1.76% YoY (still deeply loss-making).
EPS: -0.62, improved 1.64% YoY.
Gross margin: 71.33%, up 68.55% YoY (margin improvement is a bright spot, but scale is still small given revenue).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change (2026-01-23): Lake Street maintained a Buy rating but cut price target to $15 from $20.
Wall Street-style pros view: financing + Medtronic involvement is seen as transformational/validating and reduces funding uncertainty.
Wall Street-style cons view: dilution from financing and weak revenue trajectory weigh on near-term valuation and trading performance.
Influential/political flows: No recent congress trading data available; hedge fund and insider trend data show Neutral with no significant recent activity.

3 Analyst Rating

Wall Street analysts forecast AVR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVR is 19 USD with a low forecast of 15 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.220

Low

Averages

High

Current: 5.220

Low

Averages

High

Lake Street

Frank Takkinen

Buy

downgrade

$20 -> $15

AI Analysis

2026-01-23

Reason

Lake Street

Frank Takkinen

Price Target

$20 -> $15

AI Analysis

2026-01-23

downgrade

Buy

Reason

Lake Street analyst Frank Takkinen lowered the firm's price target on Anteris Technologies (AVR) to $15 from $20 and keeps a Buy rating on the shares. $320M in gross financing, which included a $90M strategic investment from Medtronic (MDT), was "a transformational deal for Anteris," says the analyst, who reduced the firm's target on the dilutive impact of the financing. However, the financing "relieves the capital overhang, verifies the product's viability, and entrenches Medtronic as a collaborator and potential acquirer," the analyst tells investors.

AVR Should I Buy

AVR Should I Buy

Should You Buy Anteris Technologies Global Corp (AVR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch